Categories: Analysts

Redknee upgraded to “Buy” at Clarus Securities

Redknee CEO Lucas Skoczkowski. Shares of Redknee Solutions (TSX:RKN) have been sliding since last autumn, but one analyst thinks the stock is currently undervalued.

Clarus analyst Eyal Ofir yesterday upgraded his rating on Redknee to “Buy”. He previously rated the stock as a “Speculative Buy”. Ofir maintained his $6.75 one-year target price on the Mississauga-based company.

Ofir, noting that Redknee’s transformative acquisition of assets from Nokia Siemens Networks is now more than a year old, says the picture of the company that has emerged is now much clearer, and he believes this means execution risk has been reduced significantly.

In recent meetings with management, the Clarus analyst says he came away with more confidence that Redknee is better positioned to execute on upgrades and expand its margins. Management, he points out, believes the opportunity in upgrading its current install base is worth more than $200-million. Ofir expects at least one contract win of between $30-100 million by the end of this year.

Ofir notes that his target price implies a P/E multiple of 21.4x his 2015 numbers, a premium to a group of comparables that includes Amdocs, Convergys and Sandvine, which trade at an average P/E multiple of 17.3x. He says Redknee deserves this premium because of its unique opportunity to drive operating leverage and revenue growth.

At press time, shares of Redknee were up .7% to $5.73.

____________________________________________________________________________________________________________

Tagged with: rkn
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Gain Therapeutics: this analyst just chopped his target

Roth Capital Partners analyst Boobalan Pachaiyappan lowered his target on Gain Therapeutics (Gain Therapeutics Stock Quote, Chart, News, Analysts, Financials… [Read More]

11 hours ago

WELLSTAR Technologies is off to a great start, this analyst says

WELLSTAR Technologies’ (WELLSTAR Technologies Corp. Stock Quote, Chart, News, Analysts, Financials TSXV:WSTR) first quarterly results as a public company exceeded… [Read More]

11 hours ago

This Canadian stock benefits from increased defense spending, analyst says

Volatus Aerospace’s (Volatus Aerospace Stock Quote, Chart, News, Analysts, Financials TSX:FLT) first Canadian Armed Forces contract and growing defence order… [Read More]

17 hours ago

Buy WELL Health Technologies for a double, this analyst says

WELL Health Technologies’ (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) Canadian clinic operations delivered strong third-quarter growth,… [Read More]

20 hours ago

Is Quarterhill (TSX:QTRH) an undervalued stock?

Quarterhill (Quarterhill  Stock Quote, Chart, News, Analysts, Financials TSX:QTRH) remains on track to complete its acquisition of Conduent’s tolling business… [Read More]

21 hours ago

This Canadian biotech stock is undervalued, analyst says

Medicenna Therapeutics’ (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) experimental cancer treatment MDNA11 produced encouraging responses in patients… [Read More]

21 hours ago